Findings From the RELEVANCE Trial in Follicular Lymphoma

November 28, 2018
Andre Goy, MD

Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab plus lenalidomide or a physician’s choice of bendamustine and rituximab plus CHOP or R-CHOP.

Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab (Rituxan) plus lenalidomide (Revlimid) or a physician’s choice of bendamustine and rituximab plus CHOP or R-CHOP.

The results indicated no difference in terms of response, progression-free survival, and overall survival. There was also a similar rate of secondary and primary malignancies, according to Goy. This is still an issue since these patients had not received chemotherapy before.